Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. [PDF]
PLoS ONE, 2014 Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at
Paolo B Abada, Stephen B Howell
doaj +1 more source
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review [PDF]
, 2007 Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Pavlakis, Nick +8 more
core +2 more sources
Treating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy [PDF]
, 2009 Objective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer.
Pavlakis, Nick +5 more
core +2 more sources
Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum
Jurnal Kesehatan, 2020 Cisplatin is a type of platinum-based chemotherapy that is often used in the spectrum of solid neoplasms, including the ovaries, testicles, urinary vesicles, colorectal, lungs, and head-neck.
Amelia Rizky Khalidah
doaj +1 more source
Downregulation of VPS13C promotes cisplatin resistance in cervical cancer by upregulating GSTP1
iScience, 2023 Summary: Cisplatin resistance remains a major obstacle limiting the effectiveness of chemotherapy in cervical cancer. However, the underlying mechanism of cisplatin resistance is still unclear.
Xiangyu Tan +9 more
doaj +1 more source
Nature Communications, 2023 Cisplatin resistance along with chemotherapy-induced neuropathic pain is an important cause of treatment failure for many cancer types and represents an unmet clinical need.
Se Jin Oh +15 more
doaj +1 more source
Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest [PDF]
, 2009 The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A recovery period
Ross Davey +3 more
core +2 more sources
Thoracic Cancer, 2021 Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in ...
Minghui Liu +8 more
doaj +1 more source
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
Molecular Cancer, 2022 Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi +18 more
doaj +1 more source
Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance [PDF]
ChemMedChem, 2014 AbstractCyclooxygenase (COX) is an enzyme involved in tumorigenesis and is associated with tumor cell resistance against platinum‐based antitumor drugs. Cisplatin analogues were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously observed in combination treatments.
Wilma, Neumann +7 more
openaire +2 more sources